<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102363">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01714960</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ99030_1001_1</org_study_id>
    <secondary_id>2012-002664-26</secondary_id>
    <nct_id>NCT01714960</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients</brief_title>
  <official_title>Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To assess the safety and tolerability of repeat dose topical administration of
           MRZ-99030 Ophthalmic Solution with ascending doses in healthy subjects (stage 1) and
           glaucoma subjects (stage 2).

        -  To assess plasma pharmacokinetics and urine concentration of MRZ- 99030 and its
           metabolite MRZ-9499 after single and repeat dose topical administration of MRZ-99030
           Ophthalmic Solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day 1 up to day 23</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Day 1 to day 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal plasma concentration (Cmax)</measure>
    <time_frame>Day 1 to day 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy Volunteers and Glaucoma Patients</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drops, 1-3 drops three times per day, duration: 16 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRZ-99030 eye drops 5mg/mL</intervention_name>
    <arm_group_label>Healthy volunteers low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRZ-99030 eye drops 20mg/mL</intervention_name>
    <arm_group_label>Healthy volunteers high dose</arm_group_label>
    <arm_group_label>Glaucoma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MRZ-99030 eye drops</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For stage 1:

        - Healthy volunteers

        For stage 2:

        - Glaucoma patients

        Exclusion Criteria:

        For stage 2:

        - Any relevant eye disease other than glaucoma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH, Early Phase Clinical Unit</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
